FOLFIRI3-aflibercept in previously treated patients with metastatic colorectal cancer

Candice Carola (1) , François Ghiringhelli (2) , Stefano Kim (3) , Thierry André (4) , Juliette Barlet (1) , Leila Bengrine-Lefevre (2) , Hélène Marijon (1) , Marie-Line Garcia-Larnicol (4) , Christophe Borg (3) , Linda Dainese (5) , Nils Steuer (4) , Hubert Richa (6) , Magdalena Benetkiewicz (7) , Annette K Larsen (8) , Aimery de Gramont (1) , Benoist Chibaudel (1)

1 Service d'Oncologie Médicale [Institut Hospitalier Franco-Britannique]
2 Département d'oncologie médicale [Centre Georges-François Leclerc]
3 Service d'Oncologie Médicale [CHRU Besançon]
4 Service d'Oncologie Médicale [CHU Saint-Antoine]
5 IPP - Institut de pathologie de Paris
6 Chirurgie viscérale endocrinienne et Cancérologique (Institut Hospitalier Franco-Britannique)
7 ARCAD - Fondation Aide et Recherche en Cancérologie Digestive (Levallois-Perret)
8 CRSA - Centre de Recherche Saint-Antoine

To evaluate the efficacy and safety of the modified FOLFIRI3-aflibercept as second-line therapy in patients with metastatic colorectal cancer.

Mots clés: Aflibercept; Chemotherapy; Colorectal cancer; Irinotecan; Second-line

Domaines: Sciences du Vivant [q-bio]; Cancer

Candice Carola, François Ghiringhelli, Stefano Kim, Thierry André, Juliette Barlet, et al.. FOLFIRI3-aflibercept in previously treated patients with metastatic colorectal cancer. World Journal of Clinical Oncology, 2018, 9 (5), pp.110 - 118. ⟨10.5306/wjco.v9.i5.110⟩. ⟨hal-01914895⟩